Athanor Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Athanor Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,089	Closed	-$326K	–	700
2020 Q2	$326K	Buy	+2,089	New	+$318K	0.02%	390
2020 Q1	–	Sell	-4,100	Closed	-$838K	–	384
2019 Q4	$838K	Sell	4,100 -1,140	-22%	-$208K	0.04%	189
2019 Q3	$421K	Buy	5,240 +2,640	+102%	+$224K	0.03%	166
2019 Q2	$245K	Buy	+2,600	New	+$224K	0.03%	117

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Athanor Capital's RETA Position: Q3 2020 in Review

Athanor Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 2,089 shares — an estimated $326K sold.

Athanor Capital first reported a position in RETA in Q2 2019 and held it in 4 quarters. The position peaked at $838K in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Athanor Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Athanor Capital sold 2,089 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $326K.
Athanor Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 4 quarters.
Athanor Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $838K in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Athanor Capital's 13F filing for Q3 2020, filed 16 Nov 2020.